Evaluation of Anticancer and Anti-Inflammatory Activities of Some Synthetic Rearranged Abietanes

Int J Mol Sci. 2023 Sep 1;24(17):13583. doi: 10.3390/ijms241713583.

Abstract

Synthesis of the rearranged abietane diterpenes pygmaeocins C and D, viridoquinone, saprorthoquinone, and 1-deoxyviroxocine has been successfully achieved. The anticancer and anti-inflammatory activities of selected orthoquinonic compounds 5, 7, 13, and 19, as well as pygmaeocin C (17), were evaluated for the first time. The antitumor properties were assessed using three cancer cell lines: HT29 colon cancer cells, Hep G2 hepatocellular carcinoma cells, and B16-F10 murine melanoma cells. Compounds 5 and 13 showed the highest cytotoxicity in HT29 cells (IC50 = 6.69 ± 1.2 µg/mL and IC50 = 2.7 ± 0.8 µg/mL, respectively). Cytometric studies showed that this growth inhibition involved phase S cell cycle arrest and apoptosis induction, possibly through the activation of the intrinsic apoptotic pathway. Morphological apoptotic changes, including nuclear fragmentation and chromatin condensation, were also observed. Furthermore, the anti-inflammatory activity of these compounds was evaluated on the basis of their ability to inhibit nitric oxide production on the lipopolysaccharide activated RAW 264.7 macrophage cell line. Although all compounds showed high anti-inflammatory activity, with percentages between 40 and 100%, the highest anti-inflammatory potential was obtained by pygmaeocin B (5) (IC50NO = 33.0 ± 0.8 ng/mL). Our results suggest that due to their dual roles, this type of compound could represent a new strategy, contributing to the development of novel anticancer agents.

Keywords: anti-inflammatory activity; antitumor activity; apoptosis; colorectal cancer; nitric oxide; rearranged abietane type; semisynthesis.

MeSH terms

  • Abietanes
  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Carcinoma, Hepatocellular*
  • HT29 Cells
  • Humans
  • Liver Neoplasms*
  • Melanoma, Experimental*
  • Mice

Substances

  • Abietanes
  • Anti-Inflammatory Agents